OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology

This three-part educational series explores the OX40 pathway and its potential in treating pediatric inflammatory skin diseases. The webinar features leading experts discussing the science behind OX40 and OX40L, emerging research, and therapeutic implications. Follow-up podcasts extend the conversation—first, with a look toward the future of OX40 therapies and the evolving concept of remission in atopic dermatitis, and then with a patient-centered dialogue highlighting how advocacy leaders are helping shape research and communication around new treatments.

Special thanks to Amgen, Sanofi, and Astria Therapeutics for their support of this independent medical education program. PeDRA is solely responsible for all program content and the selection of all presenters, authors, moderators, and faculty.

Part Three: Patient-Focused Discussion
In our final episode focused on the OX40 pathway and its emerging therapies, Dr. Joy Wan moderates a thoughtful discussion with two leaders from the patient advocacy community. Wendy Smith Begolka, MBS, Chief Program and Mission Officer at the National Eczema Association, and Korey Capozza, MPH, Founder and Executive Director of Global Parents for Eczema Research, share their perspectives on incorporating patient priorities into clinical trials and effectively communicating with patients about new and emerging treatments.

Part Two: Innovative Insights Discussion
Following the June 23 OX40 webinar, Dr. Eichenfield, Dr. Simpson, and Dr. Wan continue the conversation with a look ahead at the future of OX40 therapies and their potential to change the course of disease. They also unpack the complex concept of remission in atopic dermatitis—what it means, how it’s defined, and whether it’s truly achievable.

Part One: OX40: Innovative Insights and Emerging Clinical Trial Data
This engaging and informative webinar explores the role of OX40 and OX40L in pediatric dermatology. OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology brings together experts in the field to discuss emerging research, mechanisms of action, and the implications of targeting the OX40 pathway for treating chronic inflammatory skin diseases in children.

 

Lawrence Eichenfield, MD
Program Presenter

Relevant Disclosures:

Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.

Eric Simpson, MD
Program Presenter

Relevant Disclosures:

Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics , Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX Therapeutics

Eric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkin

Joy Wan, MD
Program Moderator

Relevant Disclosures:

Sun Pharmaceuticals – consulting (DMC), Astria Therapeutics – consulting (ad board), Galderma – fellowship funding (paid to Johns Hopkins)

Wendy Smith Begolka, MBS
Program Presenter

Relevant Disclosures:

Amgen/Kyowa Kirin, Pfizer, Sanofi  – advisory board honoraria

Arcutis, Incyte, Galderma – speaker fees

Pfizer, Sanofi – research grants

Korey Capozza, MPH
Program Presenter

Relevant Disclosures:

Advisory board honoraria from Amgen, Kyowa Kirin, Incyte, and Pfizer